source
- Early Inclusion of China Boosts Global Biotech Clinical Development EfficiencyMany global biotech firms still treat China as a later-stage commercial market, adding it only after key development decisions. This practice often forces costly bridging studies, extends timelines…
- Study finds Lilly's obesity drug Zepbound may lower hospital and ER costs for older adultsA real‑world analysis examined older patients with obesity or excess weight who were either treated with Eli Lilly’s drug Zepbound or not. The researchers tracked healthcare utilization over time t…